Imaging Biomarkers Market Report: Market Size & Forecast 2026

Imaging biomarkers are quantitative, image-derived indicators used to detect, characterize, or monitor disease and to assess response to therapy. The global market is valued at roughly $7.25 billion in 2025 and is expected to expand at a 9.54% CAGR, placing it on track to exceed $15 billion within the next decade. Private market research estimates for this segment vary widely because no government statistical agency publishes official figures, with reported 2024-2025 valuations spanning from low single-digit billions to nearly $14 billion depending on scope.

• •Estimated 2025 global value of approximately $7.25 billion with a 9.54% CAGR through the forecast horizon.
• •Imaging biomarkers are extracted from modalities including PET, MRI, CT, and ultrasound to objectively quantify disease states.
• •Market sizing is produced exclusively by private research firms, contributing to wide variation across published estimates.

Rising demand for non-invasive, quantitative tools to support earlier diagnosis and personalized treatment planning is the central engine of market growth. Pharmaceutical sponsors are increasingly incorporating imaging biomarkers as primary or secondary endpoints in oncology and neurodegenerative disease trials, accelerating commercial demand. At the same time, the integration of AI-based image analysis is improving biomarker reproducibility and enabling broader clinical adoption.

• •Growing emphasis on precision and personalized medicine is pushing adoption of imaging-based diagnostic indicators.
• •Pharmaceutical and biotech sponsors increasingly rely on imaging biomarkers as efficacy endpoints in clinical trials.
• •Advancements in AI and radiomics are enhancing biomarker extraction accuracy and throughput.

The market is commonly segmented by modality, application, and end user, with oncology representing the largest application area and neurology the fastest-growing segment due to rising prevalence of Alzheimer's and Parkinson's disease. By modality, PET and MRI account for the majority of biomarker imaging studies, while CT and ultrasound contribute growing volumes. North America holds the leading share owing to advanced healthcare infrastructure and high clinical trial activity, while Asia-Pacific is the fastest-growing region driven by expanding imaging capacity and rising healthcare investment.

• •Oncology dominates applications, with neurology expanding rapidly on the back of neurodegenerative disease prevalence.
• •PET and MRI are the leading modalities for imaging biomarker development and clinical use.
• •North America leads in revenue share; Asia-Pacific is the fastest-growing regional market.

What are the recent trends and outlook?

AI-driven radiomics, deep learning-based image quantification, and multimodal biomarker integration are reshaping the field, while regulatory acceptance of imaging biomarkers as surrogate endpoints is gradually expanding. Cloud-based platforms for image sharing and analysis are enabling multi-site trials and broader clinical use. Looking ahead, the market is expected to nearly double over the forecast horizon, supported by reimbursement expansion for quantitative imaging and growing investment in companion diagnostics.

• •Regulatory acceptance of imaging biomarkers as clinical trial endpoints is gradually strengthening.
• •Cloud and federated learning platforms are enabling scalable, multi-site biomarker analysis.
• •Companion diagnostic applications and reimbursement for quantitative imaging are expected to widen commercial adoption.